Merck KgaA-P&G Deal: Complex In Some Emerging Markets But No ‘Dis-Synergies’
This article was originally published in Scrip
Executive Summary
Merck KGaA’s sale of its global consumer health business to Procter & Gamble (P&G) is expected to be a somewhat complex affair in emerging markets like India, where it has a listed entity and a seemingly cohesive consumer health and pharma footprint, though Merck's management emphasized that no “dis-syneries” are anticipated.
You may also be interested in...
Merck KGaA Down-Plays Further Deals After Consumer Health Sell-Off
The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater flexibility in business development activities, but reducing net debt has first claim on the funds.
Interview: German Merck Set For Big "Leap" In India
Germany's Merck Group appears set to build on its strong showing in India. Belén Garijo, CEO of Healthcare at Merck KGAA, tells Scrip about efforts to "consumerize" the firm's primary care business, how Erbitux is the "backbone" on which the company will build its oncology presence, and plans to roll out new products including the clinical stage immune-oncology asset avelumab, in India.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.